Higher activity of SphK1 and SphK2 in oxaliplatin-resistant colon cancer cell line RKO and knockdown of either SphK1 or SphK2 abrogates RKO cells oxaliplatin resistance [119]. This evidence concerns the gene SPHK2 and colonic neoplasm.